Trial
NCT03559270
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
Incyte Corporation
Condition
Atopic Dermatitis
Intervention
Baricitinib
Why stopped
Terminated due to lack of alignment during regulatory negotiations.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-08